Search
Trevi Therapeutics Inc
TRVIAdd to Watchlist
15.890USD
-0.010-0.06%
Close 09-14 16:00（ET）
2.26BMarket Cap
LossP/E TTM
Trevi Therapeutics Inc (TRVI) Stock Price Target & Forecast
Analyst Rating
Based on 12 analysts giving stock ratings to Trevi Therapeutics Inc in the past month.
Buy
4 Strong Buy
8 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
29.500USD+85.53%
TRVI Analyst Recommendation Trends
In the current month, TRVI has received 8 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. TRVI average Analyst price target in the last month is 29.500.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
4
4
4
4
4
4
4
4
8
8
7
7
8
8
8
8
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
12
12
11
11
12
12
12
12
Financial Forecasting
Based on analysts' estimates, TRVI EPS is projected to reach -0.134 in FY2026Q3, following reported EPS of -0.114 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.10
-0.08
-0.11
-0.13
-0.15
Actual
-0.06
-0.09
-0.11
--
--
Surprise
+41.83%
-18.44%
-3.07%
--
--
FAQs
What is Trevi Therapeutics Inc's price target?
Analysts forecast that Trevi Therapeutics Inc's price target is USD 20.00, with the highest forecast at USD 27.00 and the lowest forecast at USD 11.00.
How have Trevi Therapeutics IncTRVI's recent earnings per share performed?
The market expectation was USD -0.11, while Trevi Therapeutics IncTRVI's earnings per share (EPS) for the previous quarter was USD -0.09. EPS for the next quarter is expected at USD -0.13.
What is the analyst rating for Trevi Therapeutics Inc?
Based on the ratings of Trevi Therapeutics Inc's stock from 12 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.